Kilickap, S. Et Al. 2018. The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey. 43rd ESMO Congress (ESMO) , (Munich, Germany), 505.

Kilickap, S., Olmez, O. F., Cicin, I., Demirci, U., Alan, O., Cabuk, D., ... Sakalar, T.(2018). The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey . 43rd ESMO Congress (ESMO) (pp.505). Munich, Germany

Kilickap, S. Et Al. "The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey," 43rd ESMO Congress (ESMO), Munich, Germany, 2018

Kilickap, S. Et Al. "The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey." 43rd ESMO Congress (ESMO) , Munich, Germany, pp.505, 2018

Kilickap, S. Et Al. (2018) . "The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey." 43rd ESMO Congress (ESMO) , Munich, Germany, p.505.

@conferencepaper{conferencepaper, author={S. Kilickap Et Al. }, title={The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey}, congress name={43rd ESMO Congress (ESMO)}, city={Munich}, country={Germany}, year={2018}, pages={505} }